The Claim
In heart transplant recipients, PCSK9 inhibitor therapy is associated with a mean reduction in low-density lipoprotein (LDL) cholesterol of 82.61 mg/dL over a 13-month follow-up period, suggesting it may serve as an effective lipid-lowering treatment for patients who are unable to tolerate statins.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people who've had a heart transplant and can't take cholesterol pills like statins, a newer medicine called a PCSK9 inhibitor might help lower their bad cholesterol by about 83 points over a year.
See the scientific wording
In heart transplant recipients, PCSK9 inhibitor therapy is associated with a mean reduction in LDL cholesterol of 82.61 mg/dL over a follow-up period of 13 months, suggesting it may be an effective lipid-lowering option for patients who cannot tolerate statins.
What the research says
1 studyThe study looked at the same medicine and patients mentioned in the claim and found the same big drop in bad cholesterol, with no serious side effects.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.